Joseph P. Eder - Researcher Profile | RDL Research Database

Publications

6 shown

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

Edward B. Garon , Naiyer A. Rizvi , Rina Hui +24 more

Pembrolizumab had an acceptable side-effect profile and showed antitumor activity in patients with advanced non-small-cell lung cancer. PD-L1 expression in at least 50% of tumor...

2015 New England Journal of Medicine 6054 citations

Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial

Tanguy Y. Seiwert , Barbara Burtness , Ranee Mehra +9 more

2016 The Lancet Oncology 1684 citations

Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial

Kei Muro , Hyun Cheol Chung , Veena Shankaran +15 more

2016 The Lancet Oncology 1096 citations

Long-term OS for patients with advanced NSCLC enrolled in the KEYNOTE-001 study of pembrolizumab (pembro).

Rina Hui , Leena Gandhi , Enric Carcereny +17 more

9026 Background: The anti–PD-1 antibody pembro (MK-3475) is approved in the US for treating PD-L1–positive NSCLC that progressed after platinum-containing chemotherapy. This app...

2016 Journal of Clinical Oncology 58 citations